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Objectives This study analyzed the antiarrhythmogenic effect of reconstituted high-density lipoprotein (rHDL) against
ischemia/reperfusion in vivo.
Background Recent studies have suggested that a reduction in the plasma HDL level may contribute to cardiac sudden
death. Although there are currently only a few therapeutic strategies for increasing HDL, an exciting new thera-
peutic option, rHDL, has recently been developed to prevent coronary artery disease.
Methods To analyze the suppression of reperfusion arrhythmia by rHDL (apolipoproteinA-I with 1-palmitoyl-2-oleoyl-
phosphatidyl-choline), 92 male Wistar rats were divided into 10 groups: rats that had been pre-treated with or
without rHDL, apolipoproteinA-I, or 1-palmitoyl-2-oleoyl-phosphatidyl-choline in the presence or absence of inhibi-
tors of Akt protein kinase, nitric oxide (NO), or extracellular-signal-regulated kinase (ERK) administered intrave-
nously before left coronary artery occlusion. We also used human coronary artery endothelial cells and adeno-
sine triphosphate-binding cassette transporter (ABC) A1-, ABCG1-, or scavenger receptor class B, type
I–transfected ldlA7 cells systems.
Results The duration of ventricular tachycardia or ventricular fibrillation after reperfusion in rHDL–pre-treated rats was
much shorter than that in untreated rats. ApolipoproteinA-I or 1-palmitoyl-2-oleoyl-phosphatidyl-choline alone
had no effect. The effect of rHDL was blocked by inhibitors of Akt, NO, and ERK. Plasma NO concentration in the
rHDL group was significantly higher. In addition, rHDL activated phospho(p)-Akt, p-ERK, and p-endothelial NO
synthesis in endothelial cells. The rHDL activated p-ERK in ABCA1- or ABCG1-transfected but not scavenger re-
ceptor class B, type I–transfected ldlA7 cells.
Conclusions The rHDL-induced NO production, probably mediated by ABCA1 or ABCG1 through an Akt/ERK/NO pathway in
endothelial cells, may suppress reperfusion-induced arrhythmias. The HDL-based therapy may hold the promise
of reducing the incidence of such arrhythmias after ischemia/reperfusion. (J Am Coll Cardiol 2008;51:
1604–12) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.040i
d
r
a
s
d
m
a
t
t
a
o
a
Hlasma high-density lipoprotein (HDL) protects against
ardiac events by mediating cholesterol efflux from the
rterial wall (reverse cholesterol transport), thereby prevent-
ng the formation of atherosclerotic plaque in coronary
rteries (1). Recent studies have suggested that a reduction
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ukuoka, Japan; †Department of Cardiovascular Medicine, and the ‡Department of
dvanced Clinical Science and Therapeutics, University of Tokyo Graduate School of
edicine, Tokyo, Japan; §Department of Cardiovascular Diseases, Fukuoka Univer-
ity Chikushi Hospital, Chikushino, Japan; and the Lipid Research Group, Heart
esearch Institute, Camperdown, Sydney, New South Wales, Australia. Supported in
art by a grant (18590826) from the Ministry of Education, Culture, Sports, Science
nd Technology, Japan, and the Central Research Institute of Fukuoka University,
apan.H
Manuscript received September 14, 2007; revised manuscript received December 4,
007, accepted December 10, 2007.n the plasma HDL level may contribute to cardiac sudden
eath (2). This contribution of HDL must be related to
everse cholesterol transport and the stabilization of vulner-
ble, unstable plaque (3). There are several reports that
uggest a direct relation between plasma high- and low-
ensity lipoproteins and fatal arrhythmia (4,5). Further-
ore, HDL has many pleiotropic effects (1), such as
ntioxidant, anti-inflammatory, and antithrombotic proper-
ies, in addition to its ability to enhance reverse cholesterol
ransport. Although HDL is a target in the treatment of
therosclerotic coronary artery disease, there are currently
nly a few therapeutic strategies for increasing HDL, such
s statins and cholesterol ester transfer protein inhibitors.
owever, an exciting new therapeutic option, reconstituted
DL (rHDL), has recently been developed and is currently
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April 22, 2008:1604–12 Antiarrhythmogenic Effect of HDLhe focus of intriguing research (6). Although pleiotropic
ffects of rHDL may protect isolated rat hearts against an
schemia/reperfusion (I/R) injury that involves the reduction
f tumor necrotic factor- and the enhancement of prosta-
landin release (7), the antiarrhythmogenic effect of rHDL
gainst I/R remains unclear in vivo.
Nitric oxide (NO) is an endogenous regulatory molecule
hat is involved in a variety of physiological activities such as
he regulation of blood pressure (BP). A previous in vitro
tudy examined HDL-stimulated NO release (1). In addi-
ion, NO is also known to trigger ischemic preconditioning
gainst I/R arrhythmia (8). For instance, an angiotensin
eceptor blocker induced an antiarrhythmogenic effect (9)
hat may be related to NO production in animal I/R models
10). Because NO is a key mediator for antiarrhythmogenic
ffects, HDL-induced NO production may protect the
eart from cardiac injury during I/R via effects on both
ardiac tissue and coronary perfusion. Therefore, we hypoth-
sized that rHDL contributed to the prevention of I/R
rrhythmia through its pleiotropic effects, such as NO pro-
uction in endothelial cells (ECs). In this study, we ana-
yzed the antiarrhythmogenic effect of rHDL using a rat I/R
rrhythmia model and cell systems.
ethods
aterials. The following antibodies and reagents were
urchased or kindly provided: PD98059, a specific inhib-
tor of extracellular-signal-regulated kinase (ERK) (Cell
ignaling Technology Inc, Danvers, Massachusetts);
-nitro-L-arginine methyl ester hydrochloride (L-
AME), a specific inhibitor of endothelial NO synthase
eNOS) (Sigma-Aldrich Co., St. Louis, Missouri); wort-
annin, a specific inhibitor of phosphoinositide 3 (PI3)
inase (Sigma-Aldrich); antibodies for Akt, phospho(p)-
kt, ERK1/2, and p-ERK1/2 (Thr202/Tyr204) (Cell Sig-
aling Technology).
reparation of rHDL. Discoidal rHDL containing 1-
almitoyl-2-oleoyl-phosphatidyl- choline (POPC) (Avanti
olar Lipids, Alabaster, Alabama) and apolipoproteinA-I
A-I) (initial POPC/A-I molar ratio 100/1) was prepared
y the cholate dialysis method as described previously (11).
nimal preparation. Male Wistar rats (250 to 350 g) were
nesthetized with 1.5% pentobarbital (60 mg/kg) intraperi-
oneally. Subdermal electrodes were placed to allow the
etermination of a lead II electrocardiogram (ECG). Myo-
ardial ischemia was induced by temporary occlusion of the
eft main coronary artery. After tracheotomy, the animals
ere ventilated with room air by a respirator for small
odents (model 683; Harvard rodent ventilator, Harvard
pparatus, Inc., Holliston, Massachusetts). The chest was
pened by a left thoracotomy and the heart was exposed.
fter incision of the pericardium to allow access to the left
ain coronary artery, the hearts were subjected to 5 min of
schemia by ligation the left main coronary artery with #6/0
ilk string. The string was removed after 5 min of coronary 1cclusion to produce reperfusion.
fter 3 min of reperfusion, blood
amples were drawn by cardiac
uncture and the heart was rap-
dly excised. Before and during
he ischemia or reperfusion pe-
iod, ECGs were recorded on a
owerLab 4/25 data acquisition
ystem (ADInstruments, Colo-
ado Springs, Colorado) with data
nalysis software (Chart v4.0, AD-
nstruments). Ventricular arrhyth-
ia was assessed in accordance
ith the definitions reported in the
ambeth Convention (12), and
he incidence and duration of ven-
ricular tachycardia (defined as 4 or
ore consecutive ventricular pre-
ature beats) and ventricular fi-
rillation (if an irregular undulat-
ng baseline was apparent) were
etermined. All studies were per-
ormed in accordance with the
uidelines described in the na-
ional animal protection law, and
he use of animal tissues was ap-
roved by the Fukuoka University
nternal Review Committee.
xperimental protocols. EXPER-
MENT 1. The effects of rHDL on
CG properties, BP, heart rate
HR), and cardiac function were
tudied. The rHDL (6 mg/kg of
-I) was injected intravenously
nto rats under sedation (pento-
arbital, intraperitoneally). In
he control group, phosphate-
uffered saline (PBS) was infused
nstead of rHDL. Changes in
CG properties (PR, QRS, and
T intervals), BP, and HR were
ecorded before injection and 10
nd 15 min after injection. The
P and HR were measured with
BP monitor (MK1100, Muro-
achi Kikai Co., Tokyo, Japan). Cardiac function was also
ecorded at the same time by transthoracic echocardiogra-
hy (NEMIO SSA-550A, Toshiba, Tokyo, Japan). Short-
nd long-axis 2-dimensional views and M-mode at the level
f papillary muscle were analyzed, and the ejection fraction
as calculated as [100  (volume in diastole-volume in
ystole)/volume in diastole].
XPERIMENT 2. The experimental design is shown in Figure
. Ninety-two male Wistar rats were randomly assigned to
Abbreviations
and Acronyms
ABC  adenosine
triphosphate-binding
cassette transporter
A-I  apolipoproteinA-I
BP  blood pressure
cGMP  cyclic guanosine
monophosphate
cITP  capillary
isotachophoresis
EC  endothelial cell
ECG  electrocardiogram
eNOS  endothelial nitric
oxide synthesis
ERK  extracellular-signal-
regulated kinase
fHDL  fast-migrating high-
density lipoprotein
HCECs  human coronary
artery endothelial cell
HDL  high-density
lipoprotein
HR  heart rate
I/R  ischemia/
reperfusion
iHDL  intermediate-
migrating high-density
lipoprotein
L-NAME  N-nitro-L-arginine
methyl ester hydrochloride
NO  nitric oxide
NOx  nitrite plus nitrate
PBS  phosphate-buffered
saline
PI3  phosphoinositide 3
POPC  1-palmitoyl-2-
oleoyl-phosphatidyl-choline
rHDL  reconstituted high-
density lipoprotein
sHDL  slow-migrating
high-density lipoprotein
SR-BI  scavenger
receptor class B, type I0 groups. In the control group, PBS was infused 10 min
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Antiarrhythmogenic Effect of HDL April 22, 2008:1604–12efore ischemic insult. The A-I, POPC, and rHDL groups
ere identical to the control group except that A-I, POPC,
r rHDL, respectively, were infused 10 min before isch-
mic insult instead of PBS. The L-NAMErHDL,
D98059rHDL, and wortmanninrHDL groups were
dentical to the rHDL group except that L-NAME,
D98059, or wortmannin, respectively, was infused 5 min
efore the infusion of rHDL. The L-NAME, PD98059,
nd wortmannin groups were identical to the L-NAME
HDL, PD98059rHDL, and wortmanninrHDL groups
xcept that rHDL was not administered. All drugs or PBS
ere administrated via a tail vein before coronary occlusion.
fter treatment, the coronary artery was occluded for 5 min
nd then reperfused for 3 min.
uantification of lipoprotein subfractions by capillary
sotachophoresis and agarose gel electrophoresis. Next,
hanges in lipoprotein subfractions after rHDL injection as
haracterized by capillary isotachophoresis (cITP) were
xamined. After tracheotomy, rats were injected with rHDL
6 mg/kg as A-I) via the tail vein. Blood samples were
rawn on disodium ethylenediaminetetra-acetate before
njection and after 5, 10, and 30 min from the common
arotid artery. Plasma lipoprotein fractions were analyzed
y cITP using a Beckman P/ACE MDQ system
Beckman-Coulter Inc., Fullerton, California), as de-
cribed previously (13).
Figure 1 Experimental Protocol
Rats underwent 5 min of occlusion of the left coronary artery followed by 3 min
of reperfusion. The control group was infused with phosphate-buffered saline
(PBS) 10 min before occlusion. In the reconstituted high-density lipoprotein
(rHDL), apolipoproteinA-I (A-I), and 1-palmitoyl-2-oleoyl-phosphatidyl-choline
(POPC) groups, rHDL (6 mg/kg as A-I), A-I (6 mg/kg), or POPC (15 mg/kg) were
infused instead of PBS. The L-NAMErHDL, PD98059rHDL, and wort-
manninrHDL groups were additionally injected with N-nitro-L-arginine methyl
ester hydrochloride (L-NAME) (10 mg/kg), PD98059 (4 mg/kg), or wortmannin
(16 g/kg), respectively, 5 min before the infusion of rHDL. The L-NAME,
PD98059, and wortmannin groups were identical to the L-NAMErHDL,
PD98059rHDL, and wortmanninrHDL groups except that rHDL was not
administered. The animals were killed immediately after reperfusion for the collec-
tion of heart and blood samples. ECG  electrocardiogram; iv  intravenously.1easurement of plasma nitrite plus nitrate levels. Plasma
itrite plus nitrate (NOx) was determined using a NO2/
O3 assay kit (Cayman Chemical, Ann Arbor, Michigan).
mmunohistochemistry. After 3 min of reperfusion, some
earts were fixed in 4% paraformaldehyde and embedded in
araffin, and 3-m sections were cut. Immunohistochemi-
al studies were performed with commercially available
olyclonal eNOS antibodies (Abcam, Cambridge, Massa-
husetts) and p-eNOS antibodies (Upstate Biotechnology
nc., Lake Placid, New York).
ell culture and transfection. Human coronary artery
Cs (HCECs) and Chinese hamster ovary cells (ldlA7)
14) were grown in media. In the experiments, cells supple-
ented without cell growth supplement were used. The
omplementary DNAs of adenosine triphosphate–binding
assette (ABC) transporter, ABCA1, ABCG1, and scaven-
er receptor class B, type I (SR-BI) cells were transfected to
dlA7 cells using the Lipofectamine 2000 liposomal reagent
Invitrogen Corporation, Carlsbad, California).
reparation of protein extract, immunoblotting. The
rocedure for cell lysis and western blot analysis of signaling
roteins has been described previously (15). To quantify the
esults for bands by densitometry, the films were scanned
nd the density of each band was measured using Image
auge 4.0 (Fujifilm, Tokyo, Japan).
tatistical analysis. Results are given as the mean 
tandard error. The significance of differences between
ean values was evaluated by an unpaired t test or one-way
nalysis of variance followed by Fisher’s protected least
ignificant difference, as appropriate. A repeated-measures
nalysis of variance was also used to evaluate changes in BP,
ardiac function, and ECG properties at 3 time points
before, 10 min after, and 15 min after injection) in the
HDL or control group. A value of p 0.05 was considered
ignificant.
esults
ffects of rHDL on sinus rhythm, BP, HR, and cardiac
unction. To analyze the acute effects of rHDL, ECG,
P, and cardiac function were recorded before injection
nd 10 and 15 min after injection (Table 1). Injection of
HDL caused no changes in ECG properties (PR, QRS,
nd QT intervals), BP, HR, or ejection fraction. There-
ore, rHDL was used for further studies with I/R
xperiments.
cute effects of rHDL injection on lipid profiles as
etermined by cITP. Plasma HDL in a healthy subject
an be separated into 3 subfractions: fast-migrating HDL
fHDL), intermediate-migrating HDL (iHDL), and slow-
igrating HDL (sHDL) (16). The fHDL consists only of
-migrating HDL, but the sHDL subfraction consists of
oth - and pre--migrating HDL (17). Figure 2A shows
ypical cITP lipoprotein profiles in Wistar rat plasma. Rat
DL contained 4 charged HDL subfractions [fHDL (peak
), iHDL (peaks 2 and 3), sHDL (peak 4)]. Figures 2B to
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April 22, 2008:1604–12 Antiarrhythmogenic Effect of HDLD show changes in HDL subfractions after rHDL injec-
ion. As shown in Figures 2B and 2C, sHDL (peak 4) had
ncreased, while fHDL (peak 1) had decreased at 5 to 10
in after injection, and these changes persisted for almost
0 min (Fig. 2D). These results suggest that changes in
Figure 2 Lipoprotein Profiles
Lipoprotein profiles as determined by capillary isotachophoresis (top panels) and
tom panels) in plasma from Wistar rats before rHDL injection (A), and 5 min (B),
peaks 2 and 3, intermediate-migrating HDL (iHDL); peaks 4, slow-migrating HDL (s
hanges in BP, Cardiac Function,nd ECG Properties in the rHDL or Control Groups
Table 1 Changes in BP, Cardiac Function,and ECG Properties in the rHDL or Control Groups
Before After 10 min After 15 min p Value
Control
SBP (mm Hg) 119 5 116 9 110 7 NS
HR (per min) 407 27 401 21 396 15 NS
EF (%) 76 4 75 3 74 2 NS
PR (ms) 50.2 1.4 49.0 1.7 49.7 1.6 NS
QRS (ms) 13.0 0.2 13.1 0.2 13.2 0.3 NS
QT (ms) 38.1 0.9 38.6 0.6 38.7 1.7 NS
rHDL
SBP (mm Hg) 110 10 110 9 106 8 NS
HR (per min) 384 7 388 11 384 10 NS
EF (%) 75 2 76 2 75 1 NS
PR (ms) 50.2 1.9 50.6 1.9 49.8 1.2 NS
QRS (ms) 13.6 0.2 13.9 0.2 13.9 0.3 NS
QT (ms) 39.0 0.4 38.8 0.5 39.8 1.0 NS
alues are shown as mean  standard error.
BP  blood pressure; ECG  electrocardiogram; EF  ejection fraction; HR  heart rate; NS 
ot significant; rHDL  reconstituted high-density lipoprotein; SBP  systolic blood pressure.ipoprotein profiles by rHDL may induce cell signaling soon
fter injection.
rrhythmias during reperfusion. As shown in Figures
A and 3B, the duration of reperfusion-induced ventric-
lar tachycardia in the rHDL group (16.5  8.8 s) was
ignificantly decreased from its control value (45.1 
0.4 s). The duration of reperfusion-induced ventricular
brillation showed a similar pattern (Fig. 3C) (rHDL
roup  0 s vs. control group  31.8  10.3 s, p 0.01).
sing A-I or POPC alone, both of which contain the
ame quantity of rHDL, did not influence the duration of
rrhythmias.
To assess the signaling pathways involved in the rHDL-
nduced suppression of arrhythmia, the rats were treated
ith rHDL in the presence of various inhibitors, such as
D98059, wortmannin, and L-NAME. Although the ad-
inistration of PD98059, wortmannin, or L-NAME alone
id not influence the duration of arrhythmia (Figs. 3B and
C), PD98059, wortmannin, or L-NAME inhibited the
ntiarrhythmogenic effect of rHDL.
he eNOS pathway mediates rHDL-induced NO pro-
uction. To evaluate whether rHDL increases NO pro-
uction through a PI3 kinase/Akt/ERK pathway, we mea-
ured the plasma NO concentration. Plasma was drawn
fter 3 min of reperfusion. The rHDL significantly in-
ofiles as analyzed by agarose gel electrophoresis and differential staining (bot-
n (C), and 30 min (D) after rHDL injection. Peak 1, fast-migrating HDL (fHDL);
Abbreviations as in Figure 1.lipid pr
10 mi
HDL).
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Antiarrhythmogenic Effect of HDL April 22, 2008:1604–12reased NOx production after I/R (rHDL group 117.5 
.5% relative to the control group; p  0.01) (Fig. 4). The
ncrease in NOx production induced by rHDL was sup-
ressed by PD98059, wortmannin, and L-NAME, suggest-
ng that rHDL protects rats from I/R arrhythmia by
Figure 3 Effects of rHDL on Reperfusion-Induced Arrhythmia
(A) Distribution of ventricular arrhythmias during reperfusion in the control group,
rat was in ventricular fibrillation (VF); the yellow cells show periods of ventricular t
dent. (B and C) Duration (in seconds) of VT (B) and VF (C) during reperfusion. *producing NO through a PI3 kinase/Akt/ERK pathway. ummunohistochemical localization of eNOS. Immuno-
istochemical tests for eNOS protein, using eNOS- and
-eNOS-specific antibodies, were performed on heart sec-
ions after reperfusion. The sections showed staining in
oronary artery ECs and capillaries (Fig. 5A). Therefore, we
roup, and L-NAMErHDL group. The orange cells are the times during which the
rdia (VT); and the gray cells are periods during which neither VF nor VT was evi-
5 for the rHDL group versus the control group. Abbreviations as in Figure 1.rHDL g
achyca
 0.0sed HCECs to examine the direct effect of rHDL on
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April 22, 2008:1604–12 Antiarrhythmogenic Effect of HDLNOS activation (Fig. 5B). Treatment of HCECs with
HDL significantly stimulated p-eNOS.
ctivation of Akt and ERK1/2 by rHDL in HCECs. To
nalyze the signal transduction from rHDL to eNOS, we
easured the activation of Akt and ERK1/2 (Fig. 6A).
ortmannin, PD98059, and L-NAME alone did not affect
kt, ERK, and eNOS activation (data not shown). The
HDL induced Akt and ERK activation. The activation of
kt was blocked by wortmannin, but not by PD98059 or
-NAME (Fig. 6B). In addition, activation of ERK was
locked by wortmannin and PD98059, but not by
-NAME (Fig. 6B).
he rHDL activated p-ERK1/2 through ABCA1 and
BCG1 in ldlA7 cells. Because ldlA7 cells are an estab-
ished epithelial lineage of nontransformed cells that are
apable of growing under serum starvation with appropriate
upplements, we used these cells as surrogate models to link
HDL to ERK in the cell membrane. To analyze what
inds of receptors mediate signaling in ldlA7 cells, we
elected SR-BI, ABCA1, and ABCG1 (Fig. 6C) because
CECs, but not ldlA7 cells, endogenously express these
eceptors by reverse transcription-polymerase chain reaction
data not shown). Although rHDL induced ERK activation
n HCECs, rHDL did not activate ERK in ldlA7 cells
ecause there may be differences in the endogenous expres-
ion of receptors or transporters between HCECs and ldlA7
ells. The rHDL in ABCA1- and ABCG1-transfected
dlA7 cells significantly stimulated p-ERK compared to
Figure 4 Plasma NO Levels
Plasma nitric oxide (NO) levels in rats: (A) NO3, (B) NO2, and (C) NOx
(NO3NO2). Blood samples were drawn by cardiac puncture at the end of
reperfusion, and plasma NO3 and NO2 levels were evaluated. The NO3, NO2,
and NOx levels (%) are shown relative to the control. The control sample was
defined as 100% NO production, and the percent increase or decrease in NO
production relative to the control was calculated for each sample. The asterisk
*p  0.05 for the rHDL group versus the rHDLL-NAME group. **p  0.01 for
the rHDL group versus the control group. ***p  0.05 for the rHDL group ver-
sus the control group. Abbreviations as in Figure 1.ock-transfected or SR-BI-transfected cells.iscussion
he main finding of the present study is that rHDL-
nduced NO production, probably through an Akt/ERK
athway in ECs, may suppress reperfusion-induced arrhyth-
ias in vivo. Furthermore, although HDL activates eNOS
ia SR-BI or sphingosine 1-phosphate (18), we found that
HDL may activate eNOS through ABCA1 or ABCG1
n ECs.
An important consequence of myocardial ischemia and
eperfusion is the occurrence of cardiac dysrhythmias. In our
n vivo study, rHDL increased NO production and sup-
ressed I/R arrhythmia. The abundance of NO in the
HDL-treated rat does not simply reflect the plasma NO
oncentration alone, and several mechanisms are related to
he increase in plasma NO. First, NO can also be generated
n the ischemic heart by the direct reduction of nitrite to
O under acidotic and highly reduced conditions (19).
econd, NO is scavenged by hemoglobin after generation
20). These mechanisms may be related to the increase in
lasma NO after rHDL injection in this study. Although
he changes in plasma NO by rHDL are quite small, many
A 
eNOS p-eNOS
10µm
Control
HDL
B 
1          2         3
0
1
2 *
(AU)
1         2       3
eNOS
p-eNOS
Time  (min)      0           5         10
rHDL 0           5          5
(µg/ml)
Figure 5 Localization and Expression Levels of eNOS
(A) Immunohistochemical staining for endothelial nitric oxide synthase (eNOS)
and phospho-eNOS (p-eNOS) from rat hearts after reperfusion in the control
and rHDL groups. Representative sections are shown (magnification 800).
(B) The rHDL activated p-eNOS after 10 min in human coronary artery endothe-
lial cells. Representative pictures are shown. The graph shows the ratio of
p-eNOS to total eNOS relative to 1.0 for no treatment. *Significant increase
(p  0.05) versus no treatment. Abbreviations as in Figure 1.
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Antiarrhythmogenic Effect of HDL April 22, 2008:1604–12tudies have suggested that low doses of NO may be
eneficial, but high doses are harmful in ischemia reperfu-
ion (21). Physiologically low concentrations of NO
educe leukocyte adhesion to endothelium, suppress in-
ammation, and increase contractility, but high concen-
rations cause depression of cardiac function by reacting
ith superoxide and forming the toxic product peroxyni-
A 1          2          3         4
ERK
p-ERK
(-) 5
Apo-AI 
1          5   (µg/ml)
rHDL
0
1
2
(AU)
0
1
2
(AU)
**
**
0
1
2
(AU) **
1        2       3        4
Akt
p-Akt
eNOS
p-eNOS
B 
1             2             3             4              5
rHDL
ERK
p-ERK
Akt
p-Akt
+ W
ortmannin
+ L-NAME
+ PD98059
Transfection (-) ABCA1 ABCG1
ERK
p-ERK
SR-BI
rHDL 0        5          0          5           0        5          0         5
(µg/ml) 
C
**
0
1
2
(AU)
0
1
2
(AU)
** *
1        2        3        4        5
1        2         3         4         5         6          7   8
1    2    3    4    5    6    7     8
0
1
2
(AU) **
Figure 6 Expression Levels of Akt, ERK, and eNOS
(A) The rHDL activated p-Akt, p-ERK, and p-eNOS after 10 min of incubation in
human coronary artery endothelial cells. (B) The rHDL-induced extracellular-
signal-regulated kinase (ERK) activation was blocked by wartmannin and
PD98059, but not L-NAME. The rHDL (5 g/ml)-induced Akt activation was
blocked by wartmannin (100 nmol/l), but not by PD98059 (3 mol/l) or
L-NAME (1 mol/l). (C) The scavenger receptor class B, type I (SR-BI), adeno-
sine triphosphate-binding cassette transporter (ABC) A1, or ABCG1 cells were
transfected into ldlA7 cells. Forty-eight hours after transfection, the cells were
cultured under serum-free conditions for an additional 24 h. The rHDL (5
g/ml) was added to the medium for 10 min, and then the cells were lysed
and analyzed. Representative pictures are shown (A to C). The graph shows
the ratio of phospho- to total eNOS, Akt, and ERK in each sample relative to
1.0 for no treatment. *Significant increase (p  0.05) versus no treatment.
Abbreviations as in Figure 1.rite (22). In addition, in our study, the change in plasma mO caused by rHDL was small, and this effect of rHDL
as abrogated by L-NAME. Therefore, NO may be a
rimary mediator. These results suggest that the produc-
ion of NO by rHDL results from activation of the
kt/ERK/NO pathway, and these effects are related to
he suppression of arrhythmia.
We also found that injection of rHDL leads to an
ncrease in sHDL and a decrease in fHDL within 5 min in
ivo. This finding agrees with our previous in vitro finding
hat both fHDL and iHDL were converted to sHDL after
he incubation of plasma with rHDL (23). The fHDL
onsisted of only -migrating HDL, but the sHDL sub-
raction consisted of both - and pre--migrating HDL
17). In addition, these findings also agree with the hypoth-
sis of Nanjee et al. (24) that the generation of small
re--HDL in vivo results from the fusion of rHDL with
ndogenous -HDL (24). Because lipid-free A-I and dis-
oidal HDL both have pre- electrophoretic mobility when
ubjected to agarose gel electrophoresis (25), newly gener-
ted pre--HDL after the injection of rHDL may contain
oth of these forms of HDL. Because the process that
romotes HDL particle fusion has the capacity to promote
he dissociation of lipid-poor A-I (25), the fusion of rHDL
ith -HDL may lead to the dissociation of lipid-poor A-I.
ur in vivo experiments show that these processes occurred
ery quickly (within 10 min), continued for at least 30
in, and may be effective for inducing cell signaling.
Both the Akt and ERK signaling are necessary for the
DL-mediated stimulation of eNOS enzymatic activity (26).
lthough the phosphorylation of PI3 kinase by rHDL may
nduce the parallel activation of Akt and ERK, which leads to
NOS activation, rHDL-induced ERK activation may be
ediated by ABCA1 or ABCG1, but not by SR-BI. We
peculated that rHDL activates eNOS through ABCA1 and
BCG1. Both ABCA1 and ABCG1 are transporters that
egulate cholesterol and phospholipid export to HDL. How-
ver, there have been several reports that ABC transporters are
mplicated in signal transduction (27). Because a lipid-free
orm of A-I (pre--HDL) interacts with ABCA1 and mature
DL interacts with ABCG1 (28), after injection of rHDL,
he newly developed pre--HDL and mature HDL may
nteract with ABCA1 and ABCG1, respectively. However,
HDL may also interact directly with ABCA1 and ABCG1.
lthough newly developed pre--migrating discoidal HDL
nd mature HDL may interact with SR-BI (1) or sphingosine
-phosphate 3 (29), these may not contribute to ERK activa-
ion in this study.
The pathogenesis of I/R injury and arrhythmia in-
olves many mechanisms (30). Recently, a growing body
f evidence has suggested that high levels of cytosolic
alcium play an important role in I/R arrhythmia (31).
oth endogenously generated NO, as well as NO donors,
ave a protective effect against I/R arrhythmia (32). The
O is also known to trigger ischemic preconditioning
gainst I/R arrhythmia (8). Several possible mechanisms
ay underlie the beneficial effects of NO on arrhythmias.
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April 22, 2008:1604–12 Antiarrhythmogenic Effect of HDLhe NO increases cyclic guanosine monophosphate
cGMP) levels through the activation of guanylyl cyclase
33). The NO-induced production of cGMP in the
yocardium plays an important role in the antiarrhyth-
ic effect of NO (34). The increase in myocardial cGMP
nhibits Ca2 influx through L-type Ca channels and
educes Ca2 overload during I/R (35). In addition,
ncreased cGMP and inhibition of Ca2 influx by NO
ay lead to coronary vasodilation (36). Thus, NO may
revent arrhythmias by reducing intracellular Ca2 over-
oad and subsequent coronary vasodilation.
Because NO also has an antioxidative effect, this effect
ay play a role in the antiarrhythmogenic activity of rHDL.
n this study, the administration of rHDL and the resulting
ncrease in NO may reduce I/R injury (37) but not myo-
ardial infarct size, because no infarct would result from the
hort occlusion. In fact, in our in vivo model of rat
yocardial infarction, there was a significant reduction in
nfarct size with rHDL administration once per week for 4
eeks (38).
Although several medications are used clinically, such as
tatins and fibrates that increase HDL, there is no clear
vidence that these drugs are efficacious toward reperfusion-
nduced arrhythmias. However, many clinical trials have
hown that these drugs reduced total cardiac events as well
s coronary events, and such a reduction of total cardiac
vents may include the reduction of sudden death caused by
eperfusion-induced arrhythmia.
tudy limitations. There are 3 important limitations in
his study. One possible limitation of this work is that the
nimal model of diseases and its treatment may not
recisely represent the human pathology and treatment.
lthough rHDL was administered before ischemia and
as given only once and for a short period, the admin-
stration of rHDL after ischemia or a more sufficient
dministration may be important for elucidating the
ptimal clinical application and precise mechanisms of
HDL. Second, although we did not measure the core
emperature of the rats, we can presume from other
tudies that the core temperature of pentobarbital-
nesthetized rats in this study must be lowered (39).
owever, we compared the arrhythmias in all groups
nder the same conditions; that is, we kept the rats at a
table room temperature (23oC) and placed the rats on an
xpanded polystyrene table to avoid a decrease in tem-
erature during the experiments. Third, to evaluate the
evelopment of NO in cardiac tissue and coronary
rteries, we needed to directly investigate the level of
NOS in the heart. It was very difficult to compare the
hanges in the level of eNOS activity in the heart.
ections from rat heart showed eNOS and p-eNOS
taining predominantly in coronary artery ECs and cap-
llaries. In addition, we examined the effect of rHDL on
rimary cultures of rat myocytes. However, rHDL had no
ffect on eNOS activation in myocytes (data not shown).
1herefore, we thought that rHDL activates eNOS in
Cs but not in myocytes in the heart.
onclusions
n summary, we have demonstrated that rHDL sup-
resses I/R arrhythmia presumably by increasing NO
roduction. The rHDL-induced NO production, proba-
ly mediated by ABCA1 or ABCG1 through an Akt/
RK/NO pathway in ECs, may suppress reperfusion-
nduced arrhythmias. This study suggests the potential of
nfusing rHDL particles as a therapeutic strategy against
ardiac sudden death after I/R.
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